All In Biotech

Drug Trial Radar · NCT06953466

Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

A Single Center, Open Label, Expanded Access Study of QRX003 Lotion in Subjects With Netherton Syndrome

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

8

Planned (sponsor's estimate)

Start

Oct 6, 2025

Primary completion

Dec 30, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
Quoin PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial (via an expanded access Treatment Protocol) is to learn if QRX003 (an investigational drug) applied topically to the skin (including up to the entire body \[except the scalp\]) works to treat the genetic disease Netherton syndrome. It will also learn about the safety of QRX003. The main questions the trial aims to answer are: 1. Does QRX003 impact the clinical presentation of NS in adults and minors by improving the clinical symptoms (diseased skin area, itch, and discomfort; based on clinical scoring, subject self-assessment, and other criteria)? 2. What medical problems do participants have when taking QRX003? 3. What percent of subjects will require rescue therapy? Participants will: Take drug QRX003 twice daily (applied topically to all affected areas of the body excluding the scalp) for 3 months, visit the clinic once every 4-6 weeks for checkups and tests, and to keep a dosing diary that records the times they applied the drug.

Conditions

  • Netherton Syndrome

Interventions

  • QRX003, 4% LotionDrug

    QRX003 Topical Lotion containing 4% active drug (serine protease inhibitor)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with 1-point reduction on IGATime frame: Up to week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Northwestern Memorial Hospital

    Chicago, Illinois · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.